University of Minnesota researchers expect to finish enrollment this week in the nation's first clinical trial of ivermectin to treat COVID-19, and the study's highly anticipated results could be only a month away. The controversial drug has been championed by opponents of COVID-19 vaccines, despite a warning from the Food and Drug Administration that ivermectin is cleared only to treat parasitic infections, head lice and certain skin conditions.
No comments:
Post a Comment